FOLH1 and posterior cortical atrophy: In 2021, Chen et al. conducted a pilot study assessing the performance of a 68Ga-prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/CT in the evaluation of treatment with neoadjuvant ABI + ADT for high-risk clinically localized PCa [24].